Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

Part of paid clinical trials in New York, New York.

Sponsor
Icahn School of Medicine at Mount Sinai
Study ID
NCT07487948
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Central Centrifugal Cicatricial Alopecia
  • Lichen Planopilaris

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Delgocitinib — DRUG
    twice-daily topical 2% cream

Study Details

This study evaluates the safety, tolerability, and biomarker effects of twice-daily topical delgocitinib 2% cream in adults with lichen planopilaris (LPP) or central centrifugal cicatricial alopecia (CCCA) over a 48-week treatment period. Approximately 30 participants will be enrolled: 15 CCCA and 15 LPP. The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS).

Key Dates

Start date
May 19, 2026
Status verified
Jun 2026
Primary completion
Apr 5, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Centrifugal Cicatricial Alopecia (CCCA)
    Individuals in the study diagnosed with CCCA are in this arm.
  • Experimental: Lichen Planopilaris (LPP)
    Individuals in the study diagnosed with LPP are in this arm.

Primary Outcome Measure

Changes in IFNγ in CA scalp in delgocitinib-treated patients [ Time Frame: Baseline to Week 36 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Icahn School of Medicine at Mount SinaiNew YorkNew York10029
Giselle Singer
[email protected]
212-241-3288
Benjamin Ungar (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY

By research site
Icahn School of Medicine at Mount Sinai· New York, NY

Related Studies